BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 7053254)

  • 1. Phase I trial of spirogermanium given by infusion in a multiple-dose schedule.
    Budman DR; Schulman P; Vinciguerra V; Degnan TJ
    Cancer Treat Rep; 1982 Jan; 66(1):173-5. PubMed ID: 7053254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous-infusion spirogermanium for the treatment of refractory carcinoma of the ovary: a phase II trial.
    Kavanagh JJ; Saul PB; Copeland LJ; Gershenson DM; Krakoff IH
    Cancer Treat Rep; 1985 Jan; 69(1):139-40. PubMed ID: 3967257
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase I study of spirogermanium given daily.
    Legha SS; Ajani JA; Bodey GP
    J Clin Oncol; 1983 May; 1(5):331-6. PubMed ID: 6668504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Metastatic cancer of the prostate: phase II study of spirogermanium (NSC 192965)].
    Bui NB; Chauvergne J; Brunet R; Richaud P; Hoerni B; Lagarde C; Le Guillou M
    Bull Cancer; 1986; 73(1):65-7. PubMed ID: 3779124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase I trial of spirogermanium administered on a continuous infusion schedule.
    Woolley PV; Ahlgren JD; Byrne PJ; Priego VM; Schein PS
    Invest New Drugs; 1984; 2(3):305-9. PubMed ID: 6511236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II evaluation of spirogermanium in advanced ovarian carcinoma.
    Brenner DE; Jones HW; Rosenshein NB; Forastiere A; Dillon M; Grumbine F; Tipping S; Burnett L; Greco FA; Wiernik PH
    Cancer Treat Rep; 1983 Feb; 67(2):193-4. PubMed ID: 6825131
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase II trial of spirogermanium in breast adenocarcinoma: a Cancer and Leukemia Group B Study.
    Budman DR; Ginsberg S; Perry M; Weinberg V; Schein P; Hanson J; Coleman M; Wood W
    Cancer Treat Rep; 1982 Aug; 66(8):1667-8. PubMed ID: 7105058
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II study of spirogermanium in the treatment of metastatic breast cancer.
    Pinnamaneni K; Yap HY; Legha SS; Blumenschein GR; Bodey GP
    Cancer Treat Rep; 1984 Sep; 68(9):1197-8. PubMed ID: 6478457
    [No Abstract]   [Full Text] [Related]  

  • 9. Pulmonary toxicity associated with spirogermanium.
    Dixon C; Hagemeister F; Legha S; Bodey G
    Cancer Treat Rep; 1984 Jun; 68(6):907-8. PubMed ID: 6733705
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II trial of spirogermanium in advanced epithelial carcinoma of the ovary.
    Weiselberg L; Budman DR; Schulman P; Vinciguerra V; Degnan TJ; Pasmantier M
    Cancer Treat Rep; 1982 Aug; 66(8):1675-6. PubMed ID: 7201885
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase II trial of spirogermanium for treatment of advanced breast cancer.
    Falkson G; Falkson HC
    Cancer Treat Rep; 1983 Feb; 67(2):189-90. PubMed ID: 6825129
    [No Abstract]   [Full Text] [Related]  

  • 12. A phase II study of spirogermanium in advanced human malignancy.
    Vogelzang NJ; Gesme DH; Kennedy BJ
    Am J Clin Oncol; 1985 Aug; 8(4):341-4. PubMed ID: 3909806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical trial of spirogermanium.
    Schein PS; Slavik M; Smythe T; Hoth D; Smith F; Macdonald JS; Woolley PV
    Cancer Treat Rep; 1980; 64(10-11):1051-6. PubMed ID: 7459890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II Eastern Cooperative Oncology Group Study of spirogermanium in previously treated lymphoma.
    Boros L; Tsiatis AA; Neiman RS; Mann RB; Glick JH
    Cancer Treat Rep; 1986 Jul; 70(7):917-8. PubMed ID: 3719586
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase I study of high-dose etoposide phosphate in man.
    Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
    Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of spirogermanium in patients with advanced carcinoma of the cervix.
    Brenner DE; Rosenshein NB; Dillon M; Jones HW; Forastiere A; Tipping S; Burnett LS; Greco FA; Wiernik PH
    Cancer Treat Rep; 1985 Apr; 69(4):457-8. PubMed ID: 3995514
    [No Abstract]   [Full Text] [Related]  

  • 17. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
    Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
    Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of spirogermanium in advanced renal cell carcinoma: a Cancer and Leukemia Group B study.
    Schulman P; Davis RB; Rafla S; Green M; Henderson E
    Cancer Treat Rep; 1984 Oct; 68(10):1305-6. PubMed ID: 6525606
    [No Abstract]   [Full Text] [Related]  

  • 19. A phase II study of spirogermanium as second line therapy in patients with poor prognosis lymphoma. An NCI Canada Clinical Trials Group Study.
    Eisenhauer E; Quirt I; Connors JM; Maroun J; Skillings J
    Invest New Drugs; 1985; 3(3):307-10. PubMed ID: 4066225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy for advanced renal cell cancer with spirogermanium: a Southwest Oncology Group Study.
    Saiers JH; Slavik M; Stephens RL; Crawford ED
    Cancer Treat Rep; 1987 Feb; 71(2):207-8. PubMed ID: 3802117
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.